CAMBRIDGE, Mass. (AP) _ Editas Medicine Inc. (EDIT) on Thursday reported a loss of $23.6 million in its second quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 43 cents.

The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 80 cents per share.

The genome editing company posted revenue of $10.7 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $6.1 million.

Editas shares have risen 24% since the beginning of the year. The stock has increased 50% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EDIT at https://www.zacks.com/ap/EDIT

Automated Insights, source Associated Press News